Mithramycin Analogues Generated by Combinatorial Biosynthesis Show Improved Bioactivity
- 15 January 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 71 (2), 199-207
- https://doi.org/10.1021/np0705763
Abstract
Plasmid pLNBIV was used to overexpress the biosynthetic pathway of nucleoside-diphosphate (NDP)-activated l-digitoxose in the mithramycin producer Streptomyces argillaceus. This led to a “flooding” of the biosynthetic pathway of the antitumor drug mithramycin (MTM) with NDP-activated deoxysugars, which do not normally occur in the pathway, and consequently to the production of the four new mithramycin derivatives 1–4 with altered saccharide patterns. Their structures reflect that NDP sugars produced by pLNBIV, namely, l-digitoxose and its biosynthetic intermediates, influenced the glycosyl transfer to positions B, D, and E, while positions A and C remained unaffected. All four new structures have unique, previously not found sugar decoration patterns, which arise from either overcoming the substrate specificity or inhibition of certain glycosyltransferases (GTs) of the MTM pathway with the foreign NDP sugars expressed by pLNBIV. An apoptosis TUNEL (=terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) assay revealed that compounds 1 (demycarosyl-3D-β-d-digitoxosyl-MTM) and 3 (deoliosyl-3C-β-d-mycarosyl-MTM) show improved activity (64.8 ± 2% and 50.3 ± 2.5% induction of apoptosis, respectively) against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7 compared with the parent drug MTM (37.8 ± 2.5% induction of apoptosis). In addition, compounds 1 and 4 (3A-deolivosyl-MTM) show significant effects on the ER-negative human breast cancer cell line MDA-231 (63.6 ± 2% and 12.6 ± 2.5% induction of apoptosis, respectively), which is not inhibited by the parent drug MTM itself (2.6 ± 1.5% induction of apoptosis), but for which chemotherapeutic agents are urgently needed.Keywords
This publication has 34 references indexed in Scilit:
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast CancerJAMA, 2006
- Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapyNucleic Acids Research, 2006
- Neoglycorandomization and Chemoenzymatic Glycorandomization: Two Complementary Tools for Natural Product DiversificationJournal of Natural Products, 2005
- Elucidation of the Glycosylation Sequence of Mithramycin Biosynthesis: Isolation of 3A‐Deolivosylpremithramycin B and Its Conversion to Premithramycin B by Glycosyltransferase MtmGIIChemBioChem, 2005
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences of the United States of America, 2003
- Antibiotic Glycosyltransferases: Antibiotic Maturation and Prospects for ReprogrammingJournal of Medicinal Chemistry, 2003
- Inhibition of c-src Transcription by Mithramycin: Structure−Activity Relationships of Biosynthetically Produced Mithramycin Analogues Using the c-src Promoter as TargetBiochemistry, 2003
- Interaction of Mithramycin and Chromomycin A3 with d(TAGCTAGCTA)2: Role of Sugars in Antibiotic−DNA RecognitionThe Journal of Physical Chemistry B, 2002
- The structures of premithramycinone and demethylpremithramycinone, plausible early intermediates of the aureolic acid group antibiotic mithramycinChemical Communications, 1998
- Solution Structure of Mithramycin Dimers Bound to Partially Overlapping Sites on DNAJournal of Molecular Biology, 1995